Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2022 · 10-Q
Revenue$239.90M$239.90M−16.2% vs Q3 2021 Net Income-$87.10M-$87.10MN/M vs Q3 2021 EPS Diluted-$1.75-$1.75N/M vs Q3 2021 Gross Profit$75,300,000−20.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$74,000,000N/M Free Cash Flowderived-$101,900,000N/M Margins · derivedGross margin31.4%−1.7 pt vs Q3 2021
Operating margin-18.9%−3.3 pt vs Q3 2021
Net margin-36.3%−22.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end